Edwards Lifesciences (EW) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Edwards Lifesciences Revenue Highlights

Latest Revenue (Y)

$6.07B

Latest Revenue (Q)

$1.55B

Main Segment (Y)

Transcatheter Heart Valves

Main Geography (Y)

UNITED STATES

Edwards Lifesciences Revenue by Period

Edwards Lifesciences Revenue by Year

Date	Revenue	Change
2025-12-31	$6.07B	11.55%
2024-12-31	$5.44B	8.57%
2023-12-31	$5.01B	-6.92%
2022-12-31	$5.38B	2.86%
2021-12-31	$5.23B	19.29%
2020-12-31	$4.39B	0.88%
2019-12-31	$4.35B	16.79%
2018-12-31	$3.72B	8.37%
2017-12-31	$3.44B	15.91%
2016-12-31	$2.96B	18.85%
2015-12-31	$2.49B	7.35%
2014-12-31	$2.32B	13.56%
2013-12-31	$2.05B	7.68%
2012-12-31	$1.90B	13.17%
2011-12-31	$1.68B	16.01%
2010-12-31	$1.45B	9.51%
2009-12-31	$1.32B	6.76%
2008-12-31	$1.24B	13.44%
2007-12-31	$1.09B	5.22%
2006-12-31	$1.04B	3.92%
2005-12-31	$997.90M	7.13%
2004-12-31	$931.50M	8.25%
2003-12-31	$860.50M	22.23%
2002-12-31	$704.00M	1.73%
2001-12-31	$692.00M	-13.93%
2000-12-31	$804.00M	-11.16%
1999-12-31	$905.00M	-

Edwards Lifesciences generated $6.07B in revenue during NA 2025, up 11.55% compared to the previous quarter, and up 138.33% compared to the same period a year ago.

Edwards Lifesciences Revenue by Quarter

Date	Revenue	Change
2025-09-30	$1.55B	1.36%
2025-06-30	$1.53B	8.46%
2025-03-31	$1.41B	1.94%
2024-12-31	$1.39B	2.32%
2024-09-30	$1.35B	-2.27%
2024-06-30	$1.39B	4.21%
2024-03-31	$1.33B	5.01%
2023-12-31	$1.27B	1.85%
2023-09-30	$1.24B	-4.02%
2023-06-30	$1.30B	-11.24%
2023-03-31	$1.46B	8.25%
2022-12-31	$1.35B	2.22%
2022-09-30	$1.32B	-4.00%
2022-06-30	$1.37B	2.44%
2022-03-31	$1.34B	0.86%
2021-12-31	$1.33B	1.49%
2021-09-30	$1.31B	-4.78%
2021-06-30	$1.38B	13.10%
2021-03-31	$1.22B	2.09%
2020-12-31	$1.19B	4.45%
2020-09-30	$1.14B	23.34%
2020-06-30	$925.00M	-18.05%
2020-03-31	$1.13B	-3.87%
2019-12-31	$1.17B	7.32%
2019-09-30	$1.09B	0.65%
2019-06-30	$1.09B	9.46%
2019-03-31	$993.00M	1.56%
2018-12-31	$977.70M	7.84%
2018-09-30	$906.60M	-3.93%
2018-06-30	$943.70M	5.46%
2018-03-31	$894.80M	0.71%
2017-12-31	$888.50M	8.16%
2017-09-30	$821.50M	-2.41%
2017-06-30	$841.80M	-4.72%
2017-03-31	$883.50M	15.08%
2016-12-31	$767.70M	3.83%
2016-09-30	$739.40M	-2.62%
2016-06-30	$759.30M	8.89%
2016-03-31	$697.30M	3.90%
2015-12-31	$671.10M	9.03%
2015-09-30	$615.50M	-0.21%
2015-06-30	$616.80M	4.49%
2015-03-31	$590.30M	-4.48%
2014-12-31	$618.00M	1.75%
2014-09-30	$607.40M	5.62%
2014-06-30	$575.10M	10.09%
2014-03-31	$522.40M	-2.54%
2013-12-31	$536.00M	8.15%
2013-09-30	$495.60M	-4.18%
2013-06-30	$517.20M	4.13%
2013-03-31	$496.70M	-2.70%
2012-12-31	$510.50M	13.98%
2012-09-30	$447.90M	-7.07%
2012-06-30	$482.00M	4.97%
2012-03-31	$459.20M	6.74%
2011-12-31	$430.20M	4.24%
2011-09-30	$412.70M	-4.29%
2011-06-30	$431.20M	6.60%
2011-03-31	$404.50M	3.08%
2010-12-31	$392.40M	12.47%
2010-09-30	$348.90M	-4.46%
2010-06-30	$365.20M	7.25%
2010-03-31	$340.50M	-1.79%
2009-12-31	$346.70M	6.45%
2009-09-30	$325.70M	-2.92%
2009-06-30	$335.50M	7.02%
2009-03-31	$313.50M	1.23%
2008-12-31	$309.70M	2.01%
2008-09-30	$303.60M	-7.33%
2008-06-30	$327.60M	10.38%
2008-03-31	$296.80M	-

Edwards Lifesciences generated $1.55B in revenue during Q3 2025, up 1.36% compared to the previous quarter, and up 112.06% compared to the same period a year ago.

Edwards Lifesciences Revenue Breakdown

Edwards Lifesciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Transcatheter Mitral And Tricuspid Therapies	$550.60M	$352.10M	$197.60M	$116.10M	$86.00M
Transcatheter Heart Valves	$4.49B	$4.11B	$3.88B	-	-
Surgical Heart Valve Therapy	$1.03B	$981.30M	$999.30M	$893.10M	$889.10M
Transcatheter Aortic Valve Replacement	-	-	$3.88B	$3.52B	$3.42B
Critical Care	-	-	$928.10M	$855.00M	$834.90M

Edwards Lifesciences's latest annual revenue breakdown by segment (product or service), as of Dec 25: Transcatheter Heart Valves (73.96%), Surgical Heart Valve Therapy (16.96%), and Transcatheter Mitral And Tricuspid Therapies (9.07%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Transcatheter Heart Valves	$1.16B	$1.15B	$1.13B	$1.04B	$1.02B	$1.04B	$1.01B	$979.40M	-	-	-	-	-	-	-	-	-	-	-	-
Transcatheter Mitral And Tricuspid Therapies	$155.70M	$145.20M	$134.50M	$105.10M	$91.10M	$83.00M	$72.90M	$56.00M	$52.40M	$47.60M	$41.60M	$31.50M	$29.70M	$27.90M	$27.00M	$25.30M	$22.30M	$22.10M	$16.30M	$13.10M
Surgical Heart Valve Therapy	$253.60M	$258.00M	$266.80M	$210.90M	$240.00M	$264.30M	$266.10M	$248.20M	$246.60M	$256.30M	$248.20M	$224.10M	$219.70M	$228.50M	$220.80M	$221.30M	$217.40M	$237.40M	$213.00M	$204.20M
Critical Care	-	-	-	-	-	-	$251.30M	$250.50M	$221.00M	$234.70M	$221.90M	$225.00M	$207.30M	$210.60M	$212.10M	$211.60M	$212.70M	$215.00M	$195.60M	$198.20M
Transcatheter Aortic Valve Replacement	-	-	-	-	-	-	-	$979.40M	$960.90M	$991.60M	$947.90M	$867.70M	$862.30M	$906.90M	$881.30M	$871.50M	$857.80M	$901.50M	$791.70M	$776.20M

Edwards Lifesciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Transcatheter Heart Valves (73.92%), Surgical Heart Valve Therapy (16.16%), and Transcatheter Mitral And Tricuspid Therapies (9.92%).

Edwards Lifesciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
UNITED STATES	$3.54B	$3.21B	$3.51B	$3.13B	$2.96B
Europe	$1.52B	$1.32B	$1.33B	$1.17B	$1.19B
JAPAN	$354.70M	$339.80M	$452.40M	$473.60M	$528.90M
Rest of World	$652.30M	$572.00M	$709.20M	$601.40M	$550.20M

Edwards Lifesciences's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (58.39%), Europe (25.01%), Rest of World (10.75%), and JAPAN (5.85%).

Quarterly Revenue by Country

Country	Dec 25	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
JAPAN	$87.50M	$90.10M	$95.30M	$60.20M	$81.40M	$87.40M	$110.80M	$112.00M	$108.40M	$117.90M	$114.10M	$111.10M	$104.10M	$122.90M	$135.50M	$138.90M	$125.90M	$131.80M	$132.30M	$129.40M
Europe	$409.60M	$387.90M	$378.20M	$298.50M	$319.80M	$335.60M	$367.80M	$344.90M	$322.30M	$336.20M	$331.10M	$290.80M	$270.10M	$302.80M	$311.10M	$309.40M	$291.10M	$309.80M	$280.00M	$265.80M
UNITED STATES	$907.00M	$907.50M	$889.70M	$643.90M	$804.60M	$816.80M	$940.70M	$894.40M	$869.90M	$895.30M	$849.10M	$795.50M	$786.80M	$800.80M	$749.50M	$739.50M	$753.20M	$795.70M	$674.70M	$671.20M
Rest of World	$333.10M	$169.00M	$98.40M	$148.60M	$146.10M	$178.90M	$182.80M	$180.30M	$180.80M	$165.30M	$150.90M	$158.00M	$147.40M	$145.10M	$141.90M	$140.00M	$138.70M	$129.60M	$125.30M	-

Edwards Lifesciences's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (52.21%), Europe (23.58%), Rest of World (19.17%), and JAPAN (5.04%).

Edwards Lifesciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
CAH	Cardinal Health	$222.58B	$65.44B
BDX	Becton, Dickinson and	$21.84B	$5.25B
HLN	Haleon	$11.30B	$2.92B
ALC	Alcon	$10.09B	$2.46B
A	Agilent	$6.83B	$1.80B
EW	Edwards Lifesciences	$6.07B	$1.55B
STE	STERIS	$5.46B	$1.50B
DXCM	DexCom	$4.66B	$1.21B
BRKR	Bruker	$3.44B	$860.50M
VEEV	Veeva Systems	$2.75B	$811.24M
ARGX	argenx SE	$1.23B	$401.00M

EW Revenue FAQ

What is Edwards Lifesciences’s yearly revenue?

Edwards Lifesciences's yearly revenue for 2025 was $6.07B, representing an increase of 11.55% compared to 2024. The company's yearly revenue for 2024 was $5.44B, representing an increase of 8.57% compared to 2023. EW's yearly revenue for 2023 was $5.01B, representing a decrease of -6.92% compared to 2022.

What is Edwards Lifesciences’s quarterly revenue?

Edwards Lifesciences's quarterly revenue for Q3 2025 was $1.55B, a 1.36% increase from the previous quarter (Q2 2025), and a 14.67% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $1.53B, a 8.46% increase from the previous quarter (Q1 2025), and a 10.56% increase year-over-year (Q2 2024). EW's quarterly revenue for Q1 2025 was $1.41B, a 1.94% increase from the previous quarter (Q4 2024), and a 6.23% increase year-over-year (Q1 2024).

What is Edwards Lifesciences’s revenue growth rate?

Edwards Lifesciences's revenue growth rate for the last 3 years (2023-2025) was 21.11%, and for the last 5 years (2021-2025) was 15.96%.

What are Edwards Lifesciences’s revenue streams?

Edwards Lifesciences's revenue streams in c 25 are Transcatheter Mitral And Tricuspid Therapies, Transcatheter Heart Valves, and Surgical Heart Valve Therapy. Transcatheter Mitral And Tricuspid Therapies generated $550.6M in revenue, accounting 9.07% of the company's total revenue, up 56.38% year-over-year. Transcatheter Heart Valves generated $4.49B in revenue, accounting 73.96% of the company's total revenue, up 9.29% year-over-year. Surgical Heart Valve Therapy generated $1.03B in revenue, accounting 16.96% of the company's total revenue, up 4.89% year-over-year.

What is Edwards Lifesciences’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Edwards Lifesciences was Transcatheter Heart Valves. This segment made a revenue of $4.49B, representing 73.96% of the company's total revenue.